These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 3037676)

  • 1. Rifabutin (ansamycin LM 427): a new rifamycin-S derivative for the treatment of mycobacterial diseases.
    O'Brien RJ; Lyle MA; Snider DE
    Rev Infect Dis; 1987; 9(3):519-30. PubMed ID: 3037676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro susceptibility of Mycobacterium avium complex and Mycobacterium tuberculosis strains to a spiro-piperidyl rifamycin.
    Woodley CL; Kilburn JO
    Am Rev Respir Dis; 1982 Sep; 126(3):586-7. PubMed ID: 6289711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimycobacterial activity in vivo of LM427 (rifabutin).
    Orme IM
    Am Rev Respir Dis; 1988 Nov; 138(5):1254-7. PubMed ID: 2849349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria.
    Dickinson JM; Mitchison DA
    Tubercle; 1987 Sep; 68(3):177-82. PubMed ID: 2834842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis.
    Heifets LB; Lindholm-Levy PJ; Flory MA
    Am Rev Respir Dis; 1990 Mar; 141(3):626-30. PubMed ID: 2155555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study of the minimal inhibitory concentration of rifabutine (Ansamycin LM 427) for Mycobacterium tuberculosis, Mycobacterium xenopi and Mycobacterium avium-intracellulare].
    Truffot-Pernot C; Giroir AM; Maury L; Grosset J
    Rev Mal Respir; 1988; 5(4):401-6. PubMed ID: 2845531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro and in vivo activity of rifabutin and rifampicin against Mycobacterium avium complex.
    Saito H; Sato K; Tomioka H
    Tubercle; 1988 Sep; 69(3):187-92. PubMed ID: 2855458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rifabutine in the treatment of mycobacterial infections resistant to rifampicin. Preliminary results. Group for the Study and Treatment of Resistant Mycobacterial Infections (GETIM)].
    Rev Mal Respir; 1989; 6(4):335-42. PubMed ID: 2552547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of nontuberculous mycobacterial infections in pediatric patients.
    Levin RH; Bolinger AM
    Clin Pharm; 1988 Jul; 7(7):545-51. PubMed ID: 2843317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of the spiropiperidyl rifamycin LM 427 on rifampicin resistant Mycobacterium tuberculosis.
    Ungheri D; Della Bruna C; Sanfilippo A
    G Ital Chemioter; 1984; 31(3):211-4. PubMed ID: 6100178
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic implications of inhibition versus killing of Mycobacterium avium complex by antimicrobial agents.
    Yajko DM; Nassos PS; Hadley WK
    Antimicrob Agents Chemother; 1987 Jan; 31(1):117-20. PubMed ID: 3032086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo chemotherapeutic activity of rifabutin (LM 427) on Mycobacterium avium-intracellulare complex.
    Sakurai N; Kuze F
    Bull Chest Dis Res Inst Kyoto Univ; 1987 Mar; 20(1-2):50-60. PubMed ID: 2836007
    [No Abstract]   [Full Text] [Related]  

  • 13. [In vitro activities of rifabutine and rifampicin against various mycobacteria, especially Mycobacterium tuberculosis and Mycobacterium avium complex].
    Saito H; Sato K; Tomioka H
    Kekkaku; 1988 Mar; 63(3):167-72. PubMed ID: 2836649
    [No Abstract]   [Full Text] [Related]  

  • 14. [Extracellular and intracellular activity of sparfloxacin against Mycobacterium avium complex and Mycobacterium xenopi].
    Gevaudan MJ; Bollet C; Mallet MN; de Lamballerie X; Sambuc R; de Micco P
    Pathol Biol (Paris); 1992 May; 40(5):443-9. PubMed ID: 1323093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages.
    Dhillon J; Mitchison DA
    Am Rev Respir Dis; 1992 Jan; 145(1):212-4. PubMed ID: 1309967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rifabutine: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis.
    Heifets LB; Lindholm-Levy PJ; Iseman MD
    Am Rev Respir Dis; 1988 Mar; 137(3):719-21. PubMed ID: 2830815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The activity of rifabutin against Mycobacterium leprae.
    Yoder LJ; Jacobson RR; Hastings RC
    Lepr Rev; 1991 Sep; 62(3):280-7. PubMed ID: 1665534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rifabutin in combination with clofazimine, isoniazid and ethambutol in the treatment of AIDS patients with infections due to opportunist mycobacteria. Groupe d'Etude et de Traitement des Infections à Mycobacteries Résistantes.
    Dautzenberg B; Truffot C; Mignon A; Rozenbaum W; Katlama C; Perronne C; Parrot R; Grosset J
    Tubercle; 1991 Sep; 72(3):168-75. PubMed ID: 1663282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.
    Brogden RN; Fitton A
    Drugs; 1994 Jun; 47(6):983-1009. PubMed ID: 7521834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinations of rifampin or rifabutine plus ethambutol against Mycobacterium avium complex. Bactericidal synergistic, and bacteriostatic additive or synergistic effects.
    Heifets LB; Iseman MD; Lindholm-Levy PJ
    Am Rev Respir Dis; 1988 Mar; 137(3):711-5. PubMed ID: 2830814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.